Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D PYXS's main value driver is MICV...

Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.